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whitish papules occurred on the face and 
neck of the patient. The papules increased 
in number and size and were resistant to 
topical application of steroids and vitamin 
D analoga. Simultaneously, the psoriasis 
flared up. The patient presented at our 
 department with more than 50 flesh-
 coloured partly umbilicated papules and 
nodules of up to 1 cm in diameter ( fig. 1 ) 
that were diagnosed as disseminated giant 
mollusca contagiosa (MC). 
 Laboratory routine parameters, in-
cluding complete blood cell count, blood 
chemistry and urine analysis, were unre-
markable except for a minor acidocytosis. 
An HIV test was negative.
 Histopathology of a nodule (shave bi-
opsy,  fig. 2 ) showed an exophytic tumour 
with epidermal hyperplasia and central 
impression forming a pouch containing 
keratinocytes filled with clustered intra-
cellular deposits.
 Therapy and Outcome 
 Efalizumab treatment was interrupted; 
a therapy with methotrexate 15 mg once a 
week as well as narrow-band UVB treat-
ment was initiated sparing the MC-affect-
ed regions. The MC were gradually re-
moved with a pair of forceps. After some 
minor relapses, a complete and stable re-
mission of the MC was achieved. The pso-
riasis was kept under control.
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 Abstract 
 Molluscum contagiosum is a common viral 
skin infection in children with atopic diathe-
sis and not rare in HIV patients. We report a 
45-year-old psoriasis patient who devel-
oped eruptive mollusca contagiosa during 
an antipsoriatic treatment with efalizumab. 
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 Case Report  
 We report a 45-year-old female patient 
who was referred to our department be-
cause of a psoriasis flare-up and the devel-
opment of skin papules following retreat-
ment with efalizumab. She had been suf-
fering from recalcitrant psoriasis vulgaris 
for 20 years and had a long history of dif-
ferent treatment modalities including ex-
tensive (repeat) UV therapy and therapy 
with fumaric acid esters. Complete remis-
sion was achieved after efalizumab 1 mg/
kg/week s.c. had been administered for 12 
weeks. After the remission had been sus-
tained by efalizumab treatment for anoth-
er 3 months, the drug was discontinued on 
advice of the physician. Two months later, 
the patient had a severe psoriasis relapse 
and the efalizumab treatment regimen 
was resumed. Three weeks later, eruptive 
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 Comment 
 MC is a common epidermotropic pox 
virus infection in children. The virus is 
transferred by direct skin contact. In pa-
tients with regular immune function, the 
virus induces an effective antiviral re-
sponse which prevents the manifestation 
of MC or leads to a complete remission of 
MC. As contact with the virus and mount-
ing of a virus-specific immune response 
usually occur during childhood, MC in-
fections are rarely found in adults. Predis-
posing factors in adults with MC are atop-
ic dermatitis and a suppressed immune 
system. MC infections are therefore com-
mon in patients with HIV infection or 
transplant patients.
 In contrast to patients with atopic der-
matitis, psoriasis patients hardly experi-
ence bacterial or viral skin infections. The 
low rate of skin infections in psoriasis pa-
tients is attributed to the activation of an-
timicrobial defence mechanisms in in-
flamed skin. However, immunosuppres-
sive systemic antipsoriatic therapy can 
predispose patients to skin infections. Ac-
cordingly, MC has been reported in pso-
riasis patients during immunosuppressive 
therapy such as methotrexate  [1] or during 
infliximab treatment in combination with 
other immunosuppressive drugs  [2, 3] .
 Efalizumab is a CD11a antibody ap-
proved for the treatment of recalcitrant 
moderate to severe psoriasis vulgaris. Efa-
lizumab inhibits T-cell activation and par-
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ticularly T-cell transmigration from blood 
vessels into the skin  [4] . The rate of infec-
tions or malignant tumours during efali-
zumab treatment for psoriasis vulgaris is 
generally not increased  [5, 6] . Therefore, 
efalizumab is considered as a safe long-
term treatment regimen.
 The exacerbation of MC under efali-
zumab therapy reported here might indi-
cate that under certain conditions efali-
zumab might assist viral infections to de-
velop and defeat the immune system. 
While MC lesions in childhood normally 
measure 1–4 mm, giant-shaped MC of 
more than 5 mm in diameter can be found 
in HIV-positive patients and patients un-
der immunosuppressive therapy  [7] . Al-
though case reports provide only little 
 evidence in general, they may prove ne c-
essary to raise the awareness of unantici-
pated adverse events in this new class of 
psoriasis drugs. This first published case 
of MC during efalizumab treatment dem-
onstrates that biological agents do not only 
offer new and effective treatment options 
for chronic inflammatory diseases, but 
may also confront us with atypical or un-
expected infections. 
 Fig. 1.  a Umbilicated papules and nodules on the face and neck.  b Detail, left cheek. 
 Fig. 2. Histology – exophytic tumour with 
epidermal hyperplasia and central impres-
sion forming a pouch containing keratino-
cytes filled with clustered intracellular de-
posits. 
 References 
 1 Lim KS, Foo CC: Disseminated molluscum 
contagiosum in a patient with chronic plaque 
psoriasis taking methotrexate. Clin Exp 
Dermatol 2007; 32: 591–593. 
 2 Wachi K, Prasertsuntarasai T, Kishimoto M, 
Uramoto K: T-cell lymphopenia associated 
with infliximab and cyclophosphamide. Am 
J Med Sci 2005; 330: 48–51. 
 3 Cursiefen C, Grunke M, Dechant C, Antoni 
C, Jünemann A, Holbach LM: Multiple bilat-
eral eyelid molluscum contagiosum lesions 
associated with TNFalpha-antibody and 
methotrexate therapy. Am J Ophthalmol 
2002; 134: 270–271. 
 4 Jullien D, Prinz JC, Langley RG, Caro I, 
Dummer W, Joshi A, Dedrick R, Natta P: T-
cell modulation for the treatment of chronic 
plaque psoriasis with efalizumab (Raptiva): 
mechanisms of action. Dermatology 2004; 
 208: 297–306. 
 5 Papp KA, Camisa C, Stone SP, Caro I, Wang 
X, Compton P, Walicke PA, Gottlieb AB: 
Safety of efalizumab in patients with moder-
ate to severe chronic plaque psoriasis: review 
of clinical data. Part II. J Cutan Med Surg 
2005; 9: 313–323. 
 6 Leonardi CL, Toth D, Cather JC, Langley RG, 
Werther W, Compton P, Kwon P, Wetherill 
G, Curtin F, Menter A: Review of malignan-
cies observed during efalizumab (Raptiva  ) 
clinical trials for plaque psoriasis. Dermatol-
ogy 2006; 213: 204–214. 
 7 Vozmediano JM, Manrique A, Petraglia S, 
Romero MA, Nieto I: Giant molluscum con-
tagiosum in AIDS. Int J Dermatol 1996; 35: 
 45–47. 
